Reshape Lifesciences INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Vyome Holdings, Inc. director Stanley D. Pomichter III was granted 17,833 stock options at an exercise price of $0.66 following the merger with Vyome Therapeutics.
Mohanjit Jolly, a director of Vyome Holdings, Inc., reported the indirect acquisition of 454,456 shares of common stock following the merger of Vyome Therapeutics, Inc. into a subsidiary of the Issuer.
Vyome Holdings Director John Tincoff III was granted 17,833 stock options following the merger with Vyome Therapeutics, Inc.
Vyome Holdings, Inc. director Shiladitya Sengupta was granted 624,432 fully vested stock options following the merger with Vyome Therapeutics.
Vyome Holdings, Inc. President and CEO, Nelabhotla Venkateswarlu, was granted 615,149 fully vested stock options following the merger with Vyome Therapeutics.
Vyome Holdings' President and CEO, Nelabhotla Venkateswarlu, acquired 7 shares of common stock following the merger with Vyome Therapeutics.
Vyome Holdings, Inc. CFO Robert Dickey IV reported the acquisition of 762 common shares following the merger with Vyome Therapeutics, Inc.
ReShape Lifesciences Inc. is urgently calling on shareholders to vote on key proposals related to its strategic transaction with Vyome Therapeutics, Inc. before the August 7, 2025, special meeting.
ReShape Lifesciences Inc. adjourned its special stockholder meeting to August 7, 2025, to further solicit votes on its proposed asset sale and merger, while stockholders approved share issuance for the merger, a reverse stock split, and executive compensation.
ReShape Lifesciences Inc. has adjourned its Special Meeting to August 7th, 2023, to allow more time for shareholders to vote on the proposed asset sale to Vyome Therapeutics and a charter amendment.
ReShape Lifesciences partially adjourned its Special Meeting of Stockholders to allow more time to solicit votes for the asset sale and charter amendment proposals, which are critical for its proposed merger with Vyome Therapeutics.
ReShape Lifesciences will host a Special Meeting of Stockholders on July 24, 2025, to vote on a merger with Vyome Therapeutics and the simultaneous sale of assets to Biorad Medisys, both unanimously recommended by the Board.
ReShape Lifesciences Inc. is urging stockholders to vote in favor of proposals to merge with Vyome Therapeutics, Inc. and sell substantially all assets to Biorad, aiming to transform the company and focus on immune-inflammatory assets.
ReShape Lifesciences Inc. has filed an 8-K announcing its proposed merger with Vyome Therapeutics, Inc. and an asset sale to Ninjour Health International Limited, alongside an investor presentation detailing Vyome's immuno-inflammation assets and strategic vision.
ReShape Lifesciences Inc. announced strategic workforce reductions to save over $750,000 annually and provided an update on its merger agreement with Vyome Therapeutics and asset sale to Biorad Medisys, with a shareholder meeting scheduled for July 24, 2025.
425: ReShape Lifesciences Provides $400,000 Loan to Vyome Therapeutics, Extends Merger Agreement Deadline
ReShape Lifesciences Inc. has agreed to loan up to $400,000 to Vyome Therapeutics, Inc. and extended the termination date of their merger agreement to June 30, 2025.
ReShape Lifesciences is set to merge with Vyome Therapeutics and sell assets to Biorad Medisys, aiming to create a US-India healthcare platform.
ReShape Lifesciences is merging with Vyome Therapeutics, selling assets to Biorad for $5.16 million, and focusing on the Lap-Band 2.0 FLEX launch amid GLP-1 market impact.
ReShape Lifesciences reports Q2 2024 financial results, announces a merger with Vyome Therapeutics, and an asset purchase agreement with Biorad Medisys, while highlighting significant cost reductions.
Thomas Stankovich, CFO of ReShape Lifesciences Inc., reports the sale of company stock to cover taxes related to the vesting of restricted stock units.
ReShape Lifesciences is set to merge with Vyome Therapeutics in an all-stock transaction while simultaneously selling its assets to Biorad Medisys for $5.16 million.